Team:USTC CHINA/Project/Overview

From 2013.igem.org

(Difference between revisions)
 
(40 intermediate revisions not shown)
Line 4: Line 4:
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/main.css?action=raw&ctype=text/css" />
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/main.css?action=raw&ctype=text/css" />
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/pro.css?action=raw&ctype=text/css" />
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/pro.css?action=raw&ctype=text/css" />
 +
<style type="text/css">
 +
</style>
</head>
</head>
<body background="https://static.igem.org/mediawiki/2013/6/62/2013ustc-china_Light_grey_bg.png">
<body background="https://static.igem.org/mediawiki/2013/6/62/2013ustc-china_Light_grey_bg.png">
Line 10: Line 12:
<div id="igemlogo"><a href="https://2013.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2013/2/26/2013ustcigem_IGEM_basic_Logo.png" alt="igem home page" width="50" height="40" /></a></div>
<div id="igemlogo"><a href="https://2013.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2013/2/26/2013ustcigem_IGEM_basic_Logo.png" alt="igem home page" width="50" height="40" /></a></div>
-
    <ul id="nav">
+
<ul id="nav">
         <li><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a></li>
         <li><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a></li>
         <li class="active"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Project</a>
         <li class="active"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Project</a>
             <ul class="subs">
             <ul class="subs">
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></li>
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></li>
-
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails">Project Details</a></li>
+
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Background">Background</a></li>
 +
                <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">Design</a></li>
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></li>
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></li>
-
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Parts">Parts</a></li>
+
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></li>
             </ul>
             </ul>
         </li>
         </li>
Line 28: Line 31:
         <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/">Modeling</a>
         <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/">Modeling</a>
               <ul class="subs">
               <ul class="subs">
-
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/ReporterSystem">Reporter System</a></li>
+
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/KillSwitch">Kill Switch</a></li>
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/B.SubtilisCulture">B.Subtilis Culture</a></li>
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/B.SubtilisCulture">B.Subtilis Culture</a></li>
-
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/MiceModeling">Mice Modeling</a></li>
+
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/DesignsofImmuneExperiments">Designs of Immune Experiments</a></li>
               </ul>
               </ul>
         </li>
         </li>
Line 43: Line 46:
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team">Members</a></li>
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team">Members</a></li>
                   <li><a href="https://igem.org/Team.cgi?year=2013&team_name=USTC_CHINA">Profile</a></li>
                   <li><a href="https://igem.org/Team.cgi?year=2013&team_name=USTC_CHINA">Profile</a></li>
-
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team/Attribution">Attribution</a></li>
+
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Attributions">Attributions</a></li>
-
                   <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team/JudgingForm">Judging Form</a></li>
+
                   <li><a href="https://igem.org/2013_Judging_Form?id=1074#iGEM_Medals">Achievements</a></li>
               </ul>
               </ul>
         </li>
         </li>
Line 59: Line 62:
<div class="conbar2">
<div class="conbar2">
<div class="leftbar" align="left">
<div class="leftbar" align="left">
-
         <div id="overview-bar" class="bassic-bar">
+
         <div id="overview-bar" class="basic-bar">
         <h1>Overview</h1>
         <h1>Overview</h1>
-
         <p>T-VACCINE——A vaccine that can initiate immune response by penetrating the skin with the aid of transdermal peptide. From now on, injections are simply history! Based on the theory of user-friendly, a special group of engineering bacteria which produce T-VACCINE is used to create a brand-new "band-aid" that can serve as a guardian of our health .</p>
+
         <p align="justify">In our world, billions of people are suffering from contagions while only parts of contagions can be effectively prevented by existing vaccines. The disadvantages of traditional vaccines, like  being produced and purified with strict requirements on temperature, have limited their application, especially in developing countries.  </p>
-
<div class="img-left-side">
+
<div align="center"><img src="https://static.igem.org/mediawiki/igem.org/e/ec/2013ustc-china_traditional_vaccine_transport.jpg" width="400" height="300" />
-
<img src="https://static.igem.org/mediawiki/2013/c/c7/2013ustc-china_tvaccine1.png" width="300" height="200">
+
<div class="atfigure" align="center" style="width:400px;font-size:14px;">Fig1. Difficult shipping in remote areas </div></div>
 +
<p align="justify">This year, our project focused on a revolutionary vaccine delivery. We bring a fresh Medication into the world, which contains an in situ expression system, and our product is a biological transdermal vaccine patch called T-vaccine. We chose <i>Bacillus subtilis</i> as chassis to establish the band-aid secreting fresh vaccines. The new vaccine consists of four engineering <i>B.subtilis</i>, each of which carried a gene circuit independently.</p>
 +
<div align="center"><img src="https://static.igem.org/mediawiki/2013/archive/e/ed/20130923171924!2013igemustc_Standardization.png" width="400" height="350" />
 +
<div class="atfigure" align="center" style="width:400px;font-size:14px;">Fig2. block-based design </div></div>
 +
<p align="justify">With an excellent transdermal peptide TD1, three of the engineering <i>B.subtilis</i> could express a series of fusion proteins (the antigen and two kinds of adjuvants), which could penetrate the skin and work as traditional vaccine molecules. The fourth bacteria are our "reporter" ,which would notify users whether the band-aid works well and when the patch can be pasted . Moreover, we designed a reliable suicide system in <i>B.subtilis</i> to ensure biosafety.</p>
 +
<div align="center"><img src="https://static.igem.org/mediawiki/2013/9/91/2013ustc-china_Needles.png" width="400" height="350" />
 +
<div class="atfigure" align="center" style="width:400px;font-size:14px;">Fig3. No Needle </div></div>
 +
<p align="justify">T-vaccine can be stored from minus 20 to 60 Celsius, which grants its great advantage transportation and enables us to reach every remote corner of the world to help eliminate contagions from our world. It is also proved that transdermal vaccine is an effective method for a variety of pathogens such as: tuberculosis, anthrax, hepatitis B and so on. Additionally, we have created a world free from needles. Consider these advantages, T-vaccine is expected to set up a  promising vaccine research and a new development orientation.</p>
</div>
</div>
-
<p>We have found a kind of transdermal peptide TD-1——a magical molecule that not only enhances the permeability of the skin but also draw filamentous bacteriophages into the skin. By combining the gene fragments of antigen, immune adjuvant LTB and Luman-recruiting factor TNLFα with that of the transdermal peptide, our team got the permeable fusion  protein. In order to obtain large amount of extracelluar protein, we chose bacillus subtilis WB800N as our expression engineering bacteria. At last, the universality of our experimental method is verified by the adoption of various antigen of existing vaccine, such as HBsAg, PA and AG85B.</p>
 
-
        </div>
 
-
        <div id="aim-bar" class="bassic-bar">
 
-
        <h1>Project contains</h1>
 
-
        <p>For in situ transdermal vaccine is real a giant project, we devide it into four lab parts. And we expect to achieve following goals.</p>
 
-
        <div id="aim-bar-col">
 
-
        <h2>Antigen</h2>
 
-
<div class="img-left-side">
 
-
<img src="https://static.igem.org/mediawiki/2013/6/62/2013ustc-china_HBsAg.png" width="300" height="200">
 
-
</div>
 
-
        <p>As the main part of T-vaccine, TD-1 is fused with antigen protein, so it can penetrate the skin and present antigen. We had designed there kinds of vaccine, which are against hepatitis B, TB and anthrax. Our ELISA test and mice test had proved their antigenicity and immunogenicity,thereby proving that T-vaccine can be generally used.</p></div>
 
-
        <div id="aim-bar-col">
 
-
        <h2>adjuvant</h2>
 
-
        <p>Similar with traditional injection vaccine, adjuvant should be added into vaccine to ensure immunity. We fused TD-1 with LTB. LT has adjuvant activity and can assist foreign antigen to induce the body to produce systemic immune response. The B submit of LTB protein has no toxic effect and it also works.</p></div>
 
-
        <div id="aim-bar-col">
 
-
        <h2>TNFα</h2>
 
-
        <p>TNFα can recruit Langerhans cell(LC), which work as antigen-presenting cells around epidermis, and improved LC’s transmission to adjacent lymph node. Because this circuit is quite similar with 1# and 2# ,while its effect might be difficult to certified, so we delay the schedule of this part. 3# is the only circuit which has not been built or tested.</p></div>
 
-
        <div id="aim-bar-col">
 
-
        <h2>Device</h2>
 
-
        <p>*****邵雪盈速度来救******</p></div>
 
-
        </div>
 
</div>
</div>
<div class="rightbar">
<div class="rightbar">
Line 91: Line 80:
<div class="clear"></div>
<div class="clear"></div>
<div id="t1"><a class="active" href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div>
<div id="t1"><a class="active" href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div>
-
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails">Project Details</a></div>
+
 
-
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Background">Background</a></div>
+
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Background">Background</a></div>
-
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">Design</a></div>
+
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">Design</a></div>
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></div>
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></div>
-
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Parts">Parts</a></div>
+
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Basic Experiment</a></div>
-
 
+
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/AdvancingWork">Advancing Work</a></div>
-
 
+
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/FutureWork">Future Work</a></div>
 +
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></div>
</div></div></div>         
</div></div></div>         
          
          
</body>
</body>
</html>
</html>

Latest revision as of 12:24, 28 October 2013

Overview

In our world, billions of people are suffering from contagions while only parts of contagions can be effectively prevented by existing vaccines. The disadvantages of traditional vaccines, like being produced and purified with strict requirements on temperature, have limited their application, especially in developing countries.

Fig1. Difficult shipping in remote areas

This year, our project focused on a revolutionary vaccine delivery. We bring a fresh Medication into the world, which contains an in situ expression system, and our product is a biological transdermal vaccine patch called T-vaccine. We chose Bacillus subtilis as chassis to establish the band-aid secreting fresh vaccines. The new vaccine consists of four engineering B.subtilis, each of which carried a gene circuit independently.

Fig2. block-based design

With an excellent transdermal peptide TD1, three of the engineering B.subtilis could express a series of fusion proteins (the antigen and two kinds of adjuvants), which could penetrate the skin and work as traditional vaccine molecules. The fourth bacteria are our "reporter" ,which would notify users whether the band-aid works well and when the patch can be pasted . Moreover, we designed a reliable suicide system in B.subtilis to ensure biosafety.

Fig3. No Needle

T-vaccine can be stored from minus 20 to 60 Celsius, which grants its great advantage transportation and enables us to reach every remote corner of the world to help eliminate contagions from our world. It is also proved that transdermal vaccine is an effective method for a variety of pathogens such as: tuberculosis, anthrax, hepatitis B and so on. Additionally, we have created a world free from needles. Consider these advantages, T-vaccine is expected to set up a promising vaccine research and a new development orientation.